AZN

EU pays 336 mln euros for doses of AstraZeneca's potential COVID-19 vaccine

Credit: REUTERS/BRENDAN MCDERMID

The European Commission has paid 336 million euros ($396 million) to secure at least 300 million doses of the potential COVID-1 vaccine being developed by British drug maker AstraZeneca, a spokesman said on Thursday.

BRUSSELS, Aug 27 (Reuters) - The European Commission has paid 336 million euros ($396 million) to secure at least 300 million doses of the potential COVID-1 vaccine being developed by British drug maker AstraZeneca AZN.L, a spokesman said on Thursday.

Brussels signed the deal on behalf of EU states for the supply of at least 300 million doses of its COVID-19 vaccine candidate. It has an option for a further 100 million, the spokesman said.

"We cannot indicate at this stage the specific pricing per dose. However, a significant part of the overall costs are funded by a contribution from the overall ESI funding for vaccines," he said, referring to the bloc's so-called emergency support instrument.

($1 = 0.8479 euros)

(Reporting by Francesco Guaraisco; Writing by Josephine Mason; Editing by Jan Harvey)

((Josephine.Mason@thomsonreuters.com; +44 207 542 7695; Reuters Messaging: josephine.mason.reuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More